## Supplementary Figures {.page_break_before}

### Cell viability and death of PC9 AXL mutants

![**Cell viability and death complete time courses of PC9 AXL mutants.** A) Fold-change confluency levels to erlotinib only-treated cells after 96h. (B-K) Cell viability measurements of PC9 AXL mutants throughout 96h normalized to initial time point 24h and erlotinib only-treated cells. (L) YOYO+ cell counts normalized to erlotinib only-treated cells after 96h. (M-V) Cell death measurements of all cell lines throughout 96h normalized to initial time point 24h.](figureS1.svg){#fig:viab_death width="100%", tag="S1"}

### Cell migration and island effect of PC9 AXL mutants

![**Cell migration and island effect of AXL mutants.** A) Fold-change relative wound density (RWD) percentage of PC9 cells to erlotinib only-treated cells after 14h. (B-K) Cell migration measurements throughout 24h. L) Fold-change K estimate of Ripley's K function to erlotinib only-treated cells. (M-V) K estiamtes of PC9 AXL mutant cells across different radii.](figureS2.svg){#fig:mig_is width="100%", tag="S2"}

### Signaling supplements

![**PCA loadings of phosphoproteomic data and signal of specific peptides.** A) PCA loadings scores B) Phosphorylation signal of AXL, EGFR, and ERK1/2.](figureS3.svg){#fig:peptides width="100%", tag="S3"}

### DDMC cluster centers and PSSM motifs

![**DDMC AXL model outputs.** DDMC cluster centers (A-E) and PSSM motifs (F-J).](figureS4.svg){#fig:peptides width="100%", tag="S4"}

